The biotechnology and pharmaceutical sectors are experiencing a significant decline in merger and acquisition (M&A) activity, reaching their lowest levels in nearly a decade. Analysts predict a potential resurgence in deal-making during January and the first quarter of 2025, particularly during the JPMorgan Healthcare Conference. The total dollar value of public market deal flow in 2024 is reported to be around half of that in 2023 at a similar point in time. Despite the downturn, some analysts suggest that competitive pressures may eventually drive prices up as companies face the challenges of achieving earnings per share growth. Additionally, there are notable discussions regarding the price-to-earnings (P/E) ratios of various biotech companies, with some firms like Sarepta Therapeutics ($SRPT) and Pfizer ($PFE) being highlighted for their low P/E ratios, while others such as Alnylam Pharmaceuticals ($ALNY) and Vertex Pharmaceuticals ($VRTX) are noted for their high P/E ratios despite profitability.